Moderna Shares Gain 560% as Analysts Signal Potential 38% Decline

Moderna (MRNA) shares have surged more than 560% this year, outpacing the S&P 500's approximately 14% gain, driven by significant regulatory and clinical milestones. Despite this performance, the average Wall Street price target of $121, according to Yahoo! Finance, suggests a 38% downside from current levels, leading several analysts to label the stock overvalued.

The rally was propelled by the approval of Moderna's influenza vaccine, mFLUSIVA, for patients aged 50 and older. While traditional flu vaccines rely on predicting prevalent strains months in advance, a process the U.S. Centers for Disease Control and Prevention notes results in 40% to 60% effectiveness, mRNA technology allows for faster manufacturing. This speed enables Moderna to select strains closer to the flu season, potentially improving the match with circulating variants. In Phase 3 studies, mFLUSIVA demonstrated greater effectiveness than traditional vaccines in a market estimated at $9 billion in 2025.

A more substantial catalyst for investors was the Phase 3 clinical trial results for intismeran autogene, a personalized cancer vaccine developed with Merck (MRK). The data showed that intismeran autogene improved recurrence-free survival in certain melanoma patients when administered alongside Merck's Keytruda, compared to Keytruda alone. These results addressed investor concerns regarding Moderna's ability to succeed outside the infectious disease sector, validating its potential entry into oncology.

Moderna's market cap has reached $77 billion despite the company remaining unprofitable and generating limited revenue. In the second quarter, the company reported top-line revenue of $145 million, up from $142 million in the year-ago period. The net loss per share narrowed to $1.97, an improvement from the $2.13 loss per share reported in the prior-year quarter.

The company is currently running clinical trials for other mRNA-based candidates across oncology, infectious diseases, and other areas. Intismeran autogene is undergoing Phase 2 and Phase 3 studies for bladder, lung, and kidney cancers, as well as other sites. While future revenue and earnings are expected to improve based on recent progress, the current valuation presents challenges.

Despite the innovative pipeline and clinical successes, the $77 billion market cap is difficult to justify given the current financials. The author notes that while the business is improving, Wall Street may be correct in assessing that the shares have risen beyond their intrinsic value. Consequently, the recommendation is to wait for a dip before initiating a position rather than buying at current levels.